Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 10,140,000 shares, a drop of 6.0% from the October 15th total of 10,790,000 shares. Based on an average trading volume of 1,340,000 shares, the days-to-cover ratio is presently 7.6 days.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AQST. HC Wainwright reiterated a "buy" rating and issued a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Leerink Partners increased their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the company an "outperform" rating in a research report on Friday, October 25th. Finally, JMP Securities restated a "market outperform" rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $9.80.

Institutional Trading of Aquestive Therapeutics

Several large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Aquestive Therapeutics by 71.7% in the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company's stock worth $13,813,000 after purchasing an additional 1,353,518 shares in the last quarter. State Street Corp boosted its stake in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company's stock worth $7,454,000 after acquiring an additional 512,682 shares in the last quarter. Blue Owl Capital Holdings LP boosted its stake in Aquestive Therapeutics by 30.3% during the second quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company's stock worth $2,964,000 after acquiring an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Aquestive Therapeutics in the second quarter worth about $594,000. Finally, Verition Fund Management LLC bought a new position in shares of Aquestive Therapeutics during the third quarter valued at approximately $995,000. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Stock Performance

AQST stock traded up $0.20 on Monday, reaching $4.64. The company's stock had a trading volume of 1,454,303 shares, compared to its average volume of 1,752,910. The business has a fifty day simple moving average of $4.99 and a two-hundred day simple moving average of $3.88. The firm has a market cap of $423.07 million, a PE ratio of -9.80 and a beta of 2.82. Aquestive Therapeutics has a 12-month low of $1.73 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $13.54 million for the quarter, compared to analysts' expectations of $12.69 million. During the same quarter last year, the firm earned ($0.03) earnings per share. As a group, research analysts anticipate that Aquestive Therapeutics will post -0.47 earnings per share for the current fiscal year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.